Skip to main content

Virus-mimetic nanoparticles for diabetic nephropathy

Ref-Nr: TA-B79122


  • Specific drug delivery via nanoparticles
  • Virus like targeting in a two-stage process
  • Dose reduction compared to free drug


Poor target cell specificity is currently a major shortcoming of nanoparticles used for biomedical applications. It causes significant material loss to off-target sites and poor availability at the intended delivery site. To overcome this limitation, designed nano-particles that identify cells in a virus-like manner could provide a solution to this problem.

Bilder & Videos


The invention described here involves virus-mimetic nanoparticles that are able to transport drugs into the mesangium of the kidney. The nanoparticles use a novel sequential recognition process that is used in a similar way by viruses to recognize their target cells. In contrast to other nanomaterials, the virus-mimetic particles are able to effectively accumulate in the cells of the mesangium. By encapsulating drug candidates such as pirfenidone or cinaciguat, a rational treatment of diabetic nephropathy can be promised for the first time, which occurs in 40% of the more than 400 million people with diabetes worldwide and for whom there is currently no treatment option other than dialysis and organ transplantation.


Drug Delivery for Diabetic Nephropathy

Bayerische Patentallianz GmbH

089 5480177-0
Destouchesstr. 68
80796 München



Angebot Anbieter-Website

Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg

c/o TransMIT GmbH
Kerkrader Straße 3
D-35394 Gießen